Biocytogen Pharmaceuticals (Beijing) Co Ltd is a China-based company primarily engaged in the provision of innovative animal models and pre-clinical pharmaceutical research and development services based on its independently developed gene-editing technology. The Company utilizes its self-developed RenMice fully human antibody and T-cell receptor (TCR) mouse platform for large-scale drug discovery and development targeting potential drug targets in the human body. The Companyâ€™s main businesses include the sale of innovative animal models, pre-clinical pharmacology and efficacy evaluation services, and antibody development. The Company is also engaged in the provision of gene-editing services. The Company operates its businesses in the domestic market and overseas markets.

Employees

1,922

Sector

Biotechnology & Medical Research

Calendar

10-29 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
26-10-27	CN¥40.04	+0.15%	2,416,789
26-10-26	CN¥39.98	-3.66%	1,583,000
26-10-23	CN¥41.50	+0.68%	3,017,130
26-10-22	CN¥41.22	-9.37%	2,940,000
26-10-21	CN¥45.48	-3.85%	3,415,059

End-of-day quote Hong Kong S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

34.04CNY

Average target price

53.66CNY

Spread / Average Target

+57.64%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Revisions to estimates

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Company calendar

End-of-day quote Hong Kong S.E. 2026-10-27			5-day change	1st Jan Change
40.04 ^CNY	+0.15%		-15.35%	+13.43%

09-17	Biocytogen Pharmaceuticals Adjusts Fundraising Project, Extends Timeline	MT
09-02	Biocytogen Pharmaceuticals Co., Ltd. Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical Co., Ltd. for A Fully Human VHH Antibody	CI

Market Cap	30.02B 4.5B 4.04B 3.73B 3.38B 6.32B 428B 6.4B 44.73B 17.77B 224B 16.9B 16.54B 711B	P/E 2026 *	39.6x	P/E 2027 *	25.1x
Enterprise Value	30.02B 4.5B 4.04B 3.73B 3.38B 6.32B 428B 6.4B 44.73B 17.77B 224B 16.9B 16.54B 711B	EV / Sales 2026 *	15.4x	EV / Sales 2027 *	11.4x
Free-Float	66.45%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Hong Kong S.E.	2315	End-of-day quote
Hong Kong S.E.	2315	Delayed
Deutsche Boerse AG	I54	Delayed
Boerse Muenchen	I54	Real-time

09-17	Biocytogen Pharmaceuticals Adjusts Fundraising Project, Extends Timeline	MT
09-02	Biocytogen Pharmaceuticals Co., Ltd. Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical Co., Ltd. for A Fully Human VHH Antibody	CI
08-28	Biocytogen Pharmaceuticals Beijing H1 Profit Jumps 402%; Shares Fall 3%	MT
08-27	Biocytogen Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-07	Biocytogen Pharmaceuticals Expects H1 Profit to Soar by Up to 413%; Shares Up 10%	MT
08-06	Biocytogen Pharmaceuticals Co., Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2026	CI
07-07	Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody Adc Development	CI
06-29	Shanghai Court Dismisses HBM Subsidiary's Patent Infringement Claim Against Biocytogen	MT
06-29	Chinese Biopharma Stocks Rally as Investors Favor Healthcare Over AI	DJ
06-21	Biocytogen Pharmaceuticals Co., Ltd.(XSSC:688796) added to S&P Global BMI Index	CI
05-26	Biocytogen Launches Rensuper Workstation and Rensuper High-Throughput Antibody Manufacturing Automation Center	CI
04-27	Biocytogen Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-27	Biocytogen Pharmaceuticals Turns to Profit in Q1	MT

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Stock

Stocks

2315

CNE100005D27

Biotechnology & Medical Research

Valuation: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Chart: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Latest news: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Press Releases: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

News in other languages: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Annual profits - Rate of surprise

09-02	Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience	BU
09-02	Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience	BU
07-07	Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development	BU
07-07	Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development	BU
06-29	Court Clears Biocytogen’s RenNano® in Landmark Patent Dispute Against Harbour	BU

09-02	Biocytogen schließt nicht-exklusive Lizenzvereinbarung mit Qilu Pharmaceutical über einen vollständig humanen VHH-Antikörper zur Unterstützung der innovativen Arzneimittelentwicklung im Bereich der Neurowissenschaften
07-07	Biocytogen et Whitehawk Therapeutics concluent une collaboration mondiale pour le développement d’ADC à anticorps bispécifiques
07-07	Biocytogen und Whitehawk Therapeutics vereinbaren weltweite Zusammenarbeit zur Entwicklung von bispezifischen Antikörper-Wirkstoff-Konjugaten (ADC)
06-29	Gericht gibt Biocytogen im wegweisenden Patentstreit gegen Harbour in Bezug auf RenNano® Recht
06-29	MÄRKTE ASIEN/Positive Vorzeichen überwiegen - Anleger setzen auf Ende des Iran-Kriegs

1 day	+0.15%
1 week	-15.35%
Current month	-42.80%
1 month	-41.38%
3 months	-25.99%
6 months	-31.96%
Current year	+13.43%

1 week	39.12	46.16
1 month	39.12	80.65
Current year	33.14	80.65
1 year	23.94	80.65
3 years	5.6	80.65
5 years	5.6	80.65
10 years	5.6	80.65

Manager	Title	Age	Since
Yue Lei Shen CEO	Chief Executive Officer	57	2009-11-12
Liu Bin DFI	Director of Finance/CFO	58	2020-01-04
Sabrina Wang COO	Chief Operating Officer	47	2019-09-30

Director	Title	Age	Since
Feng Mao Hua BRD	Director/Board Member	57	2021-07-04
Xiao Yan Liang BRD	Director/Board Member	60	2020-12-14
Lei Di Zhang BRD	Director/Board Member	46	2022-11-06

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/17/26	Yan Li	Other	Director	-260	0.0002%
1/12/26	Yan Li	Other	Director	1,000	0.0009%
9/26/25	Jian Ni	Other	Director	1,300,500	1.1739%

	2026 *	2027 *
Net sales	1.94B 292M 262M 242M 219M 409M 27.69B 414M 2.9B 1.15B 14.51B 1.09B 1.07B 46.02B	2.64B 396M 355M 328M 297M 556M 37.57B 562M 3.93B 1.56B 19.69B 1.48B 1.45B 62.45B
Net income	384M 57.58M 51.68M 47.72M 43.27M 80.88M 5.47B 81.87M 572M 227M 2.87B 216M 212M 9.09B	605M 90.72M 81.42M 75.18M 68.18M 127M 8.62B 129M 901M 358M 4.52B 341M 333M 14.32B
Net Debt	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.	+0.15%	-15.35%	+57.27%	+239.32%	4.57B
WUXI APPTEC CO., LTD.	-3.10%	-4.19%	+32.67%	+59.47%	65.28B
ARGENX SE	+0.33%	+0.33%	+10.16%	+78.07%	54.57B
LONZA GROUP AG	+0.16%	+1.73%	+9.89%	+102.10%	53.59B
IQVIA HOLDINGS INC.	-0.75%	+1.38%	+24.89%	+50.91%	45.03B
BEONE MEDICINES AG	-1.30%	-4.80%	+16.05%	+114.76%	42.17B
REVOLUTION MEDICINES, INC.	+1.26%	-5.26%	+221.12%	+900.64%	39.42B
CELLTRION, INC.	-0.74%	-4.46%	+11.00%	+44.65%	32.71B
GENMAB A/S	+1.11%	+15.18%	+60.27%	+49.33%	26.5B
WUXI BIOLOGICS (CAYMAN) INC.	+3.22%	-6.72%	+25.35%	-8.75%	24.01B
Average	+0.03%	-1.35%	+46.87%	+163.05%	38.78B
Weighted average by Cap.	-0.34%	-0.72%	+42.69%	+154.44%